Selected research
Industry Growth & Trends
Global Nano Antibodies Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Nano Antibodies market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Nano Antibodies is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Nano Antibodies market include Absolute Antibody, Alpalife (Shenzhen kangti Co., Ltd.), Alphamab Oncology, Beroni Group, ChromoTek GmbH, Cusabio Technology LLC., DiosCURE Therapeutics SE, ExeVir Bio BV and Genscript, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Nano Antibodies market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Nano Antibodies market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Nano Antibodies market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Nano Antibodies.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Nano Antibodies market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Nano Antibodies Market by Company
Absolute Antibody
Alpalife (Shenzhen kangti Co., Ltd.)
Alphamab Oncology
Beroni Group
ChromoTek GmbH
Cusabio Technology LLC.
DiosCURE Therapeutics SE
ExeVir Bio BV
Genscript
PerkinElmer Inc. (BioLegend, Inc.)
Sensei Biotherapeutics, Inc.
Taisho Pharmaceutical Holdings
Merck KGaA
Novartis AG
Thermo Fisher Scientific Inc.
Sanofi (Ablynx)
Nano Antibodies Segment by Type
Fusion Nanobody
Multivalent and multispecific Nanobodies
Monovalent Nanobody
Nano Antibodies Segment by Application
Tumor targeted therapy
Circulatory disease
Disease detection in vitro
Non-invasive diagnosis in vivo
Nervous system disease
Infectious disease
Other
Nano Antibodies Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nano Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nano Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nano Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Nano Antibodies companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Fusion Nanobody
- Multivalent and multispecific Nanobodies
- Monovalent Nanobody
Applications
- Tumor targeted therapy
- Circulatory disease
- Disease detection in vitro
- Non-invasive diagnosis in vivo
- Nervous system disease
- Infectious disease
- Other
Companies covered
- Absolute Antibody
- Alpalife (Shenzhen kangti Co., Ltd.)
- Alphamab Oncology
- Beroni Group
- ChromoTek GmbH
- Cusabio Technology LLC.
- DiosCURE Therapeutics SE
- ExeVir Bio BV
- Genscript
- PerkinElmer Inc. (BioLegend, Inc.)
- Sensei Biotherapeutics, Inc.
- Taisho Pharmaceutical Holdings
- Merck KGaA
- Novartis AG
- Thermo Fisher Scientific Inc.
- Sanofi (Ablynx)
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Nano Antibodies Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Nano Antibodies Market Size by Region (2021-2032)
- 1.4.1 Global Nano Antibodies Market Size by Region (2021-2026)
- 1.4.2 Global Nano Antibodies Market Size by Region (2027-2032)
- 1.5 Key Regions Nano Antibodies Market Size (2021-2032)
- 1.5.1 North America Nano Antibodies Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Nano Antibodies Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Nano Antibodies Market Size Growth Rate (2021-2032)
- 1.5.4 South America Nano Antibodies Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Nano Antibodies Market Size Growth Rate (2021-2032)
2 Nano Antibodies Market by Type
- 2.1 Type Introduction
- 2.1.1 Fusion Nanobody
- 2.1.2 Multivalent and multispecific Nanobodies
- 2.1.3 Monovalent Nanobody
- 2.2 Global Nano Antibodies Market Size by Type
- 2.2.1 Global Nano Antibodies Market Size Overview by Type (2021-2032)
- 2.2.2 Global Nano Antibodies Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Nano Antibodies Market Size Forecasted by Type (2027-2032)
- 2.3 Global Nano Antibodies Market Size by Regions
- 2.3.1 North America Nano Antibodies Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Nano Antibodies Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Nano Antibodies Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Nano Antibodies Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Nano Antibodies Market Size Breakdown by Type (2021-2026)
3 Nano Antibodies Market by Application
- 3.1 Type Introduction
- 3.1.1 Tumor targeted therapy
- 3.1.2 Circulatory disease
- 3.1.3 Disease detection in vitro
- 3.1.4 Non-invasive diagnosis in vivo
- 3.1.5 Nervous system disease
- 3.1.6 Infectious disease
- 3.1.7 Other
- 3.2 Global Nano Antibodies Market Size by Application
- 3.2.1 Global Nano Antibodies Market Size Overview by Application (2021-2032)
- 3.2.2 Global Nano Antibodies Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Nano Antibodies Market Size Forecasted by Application (2027-2032)
- 3.3 Global Nano Antibodies Market Size by Regions
- 3.3.1 North America Nano Antibodies Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Nano Antibodies Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Nano Antibodies Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Nano Antibodies Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Nano Antibodies Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Nano Antibodies Industry Trends
- 4.2 Nano Antibodies Industry Drivers
- 4.3 Nano Antibodies Industry Opportunities and Challenges
- 4.4 Nano Antibodies Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Nano Antibodies Revenue (2021-2026)
- 5.2 Global Nano Antibodies Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Nano Antibodies Key Company Headquarters & Area Served
- 5.4 Global Nano Antibodies Company, Product Type & Application
- 5.5 Global Nano Antibodies Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Nano Antibodies Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Nano Antibodies Players Market Share by Revenue in 2025
- 5.6.3 2025 Nano Antibodies Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Absolute Antibody
- 6.1.1 Absolute Antibody Company Information
- 6.1.2 Absolute Antibody Business Overview
- 6.1.3 Absolute Antibody Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Absolute Antibody Nano Antibodies Product Portfolio
- 6.1.5 Absolute Antibody Recent Developments
- 6.2 Alpalife (Shenzhen kangti Co., Ltd.)
- 6.2.1 Alpalife (Shenzhen kangti Co., Ltd.) Company Information
- 6.2.2 Alpalife (Shenzhen kangti Co., Ltd.) Business Overview
- 6.2.3 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Alpalife (Shenzhen kangti Co., Ltd.) Nano Antibodies Product Portfolio
- 6.2.5 Alpalife (Shenzhen kangti Co., Ltd.) Recent Developments
- 6.3 Alphamab Oncology
- 6.3.1 Alphamab Oncology Company Information
- 6.3.2 Alphamab Oncology Business Overview
- 6.3.3 Alphamab Oncology Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Alphamab Oncology Nano Antibodies Product Portfolio
- 6.3.5 Alphamab Oncology Recent Developments
- 6.4 Beroni Group
- 6.4.1 Beroni Group Company Information
- 6.4.2 Beroni Group Business Overview
- 6.4.3 Beroni Group Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Beroni Group Nano Antibodies Product Portfolio
- 6.4.5 Beroni Group Recent Developments
- 6.5 ChromoTek GmbH
- 6.5.1 ChromoTek GmbH Company Information
- 6.5.2 ChromoTek GmbH Business Overview
- 6.5.3 ChromoTek GmbH Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 ChromoTek GmbH Nano Antibodies Product Portfolio
- 6.5.5 ChromoTek GmbH Recent Developments
- 6.6 Cusabio Technology LLC.
- 6.6.1 Cusabio Technology LLC. Company Information
- 6.6.2 Cusabio Technology LLC. Business Overview
- 6.6.3 Cusabio Technology LLC. Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Cusabio Technology LLC. Nano Antibodies Product Portfolio
- 6.6.5 Cusabio Technology LLC. Recent Developments
- 6.7 DiosCURE Therapeutics SE
- 6.7.1 DiosCURE Therapeutics SE Company Information
- 6.7.2 DiosCURE Therapeutics SE Business Overview
- 6.7.3 DiosCURE Therapeutics SE Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 DiosCURE Therapeutics SE Nano Antibodies Product Portfolio
- 6.7.5 DiosCURE Therapeutics SE Recent Developments
- 6.8 ExeVir Bio BV
- 6.8.1 ExeVir Bio BV Company Information
- 6.8.2 ExeVir Bio BV Business Overview
- 6.8.3 ExeVir Bio BV Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 ExeVir Bio BV Nano Antibodies Product Portfolio
- 6.8.5 ExeVir Bio BV Recent Developments
- 6.9 Genscript
- 6.9.1 Genscript Company Information
- 6.9.2 Genscript Business Overview
- 6.9.3 Genscript Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Genscript Nano Antibodies Product Portfolio
- 6.9.5 Genscript Recent Developments
- 6.10 PerkinElmer Inc. (BioLegend, Inc.)
- 6.10.1 PerkinElmer Inc. (BioLegend, Inc.) Company Information
- 6.10.2 PerkinElmer Inc. (BioLegend, Inc.) Business Overview
- 6.10.3 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 PerkinElmer Inc. (BioLegend, Inc.) Nano Antibodies Product Portfolio
- 6.10.5 PerkinElmer Inc. (BioLegend, Inc.) Recent Developments
- 6.11 Sensei Biotherapeutics, Inc.
- 6.11.1 Sensei Biotherapeutics, Inc. Company Information
- 6.11.2 Sensei Biotherapeutics, Inc. Business Overview
- 6.11.3 Sensei Biotherapeutics, Inc. Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 Sensei Biotherapeutics, Inc. Nano Antibodies Product Portfolio
- 6.11.5 Sensei Biotherapeutics, Inc. Recent Developments
- 6.12 Taisho Pharmaceutical Holdings
- 6.12.1 Taisho Pharmaceutical Holdings Company Information
- 6.12.2 Taisho Pharmaceutical Holdings Business Overview
- 6.12.3 Taisho Pharmaceutical Holdings Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Taisho Pharmaceutical Holdings Nano Antibodies Product Portfolio
- 6.12.5 Taisho Pharmaceutical Holdings Recent Developments
- 6.13 Merck KGaA
- 6.13.1 Merck KGaA Company Information
- 6.13.2 Merck KGaA Business Overview
- 6.13.3 Merck KGaA Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Merck KGaA Nano Antibodies Product Portfolio
- 6.13.5 Merck KGaA Recent Developments
- 6.14 Novartis AG
- 6.14.1 Novartis AG Company Information
- 6.14.2 Novartis AG Business Overview
- 6.14.3 Novartis AG Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Novartis AG Nano Antibodies Product Portfolio
- 6.14.5 Novartis AG Recent Developments
- 6.15 Thermo Fisher Scientific Inc.
- 6.15.1 Thermo Fisher Scientific Inc. Company Information
- 6.15.2 Thermo Fisher Scientific Inc. Business Overview
- 6.15.3 Thermo Fisher Scientific Inc. Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Thermo Fisher Scientific Inc. Nano Antibodies Product Portfolio
- 6.15.5 Thermo Fisher Scientific Inc. Recent Developments
- 6.16 Sanofi (Ablynx)
- 6.16.1 Sanofi (Ablynx) Company Information
- 6.16.2 Sanofi (Ablynx) Business Overview
- 6.16.3 Sanofi (Ablynx) Nano Antibodies Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Sanofi (Ablynx) Nano Antibodies Product Portfolio
- 6.16.5 Sanofi (Ablynx) Recent Developments
7 North America
- 7.1 North America Nano Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Nano Antibodies Market Size by Country (2021-2026)
- 7.3 North America Nano Antibodies Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Nano Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Nano Antibodies Market Size by Country (2021-2026)
- 8.3 Europe Nano Antibodies Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Nano Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Nano Antibodies Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Nano Antibodies Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Nano Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Nano Antibodies Market Size by Country (2021-2026)
- 10.3 South America Nano Antibodies Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Nano Antibodies Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Nano Antibodies Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Nano Antibodies Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst